Associations with methacholine sensitivity expressed as DRS in SCD and control subjects
| Clinical factors | DRS SCD Spearman r (95% CI) | p Value | DRS control Spearman r (95% CI) | p Value |
|---|---|---|---|---|
| zFEV1/FVC | −0.04 (−0.33 to 0.26); n=46 | 0.780 | −0.36 (−0.59 to 0.08); n=47 | 0.012 |
| FeNO | 0.25 (−0.05 to 0.5); n=46 | 0.096 | 0.33 (0.04 to 0.57); n=47 | 0.023 |
| Blood eosinophil count | 0.07 (−0.32 to 0.44); n=28 | 0.708 | 0.50 (0.15 to 0.74); n=29 | 0.006 |
| Total serum IgE | −0.08 (−0.04 to 0.23); n=44 | 0.607 | 0.18 (−0.12 to 0.45); n=47 | 0.216 |
| Hb | −0.08 (−0.36 to 0.22); n=46 | 0.611 | −0.03 (−0.32 to 0.27); n=47 | 0.837 |
| Reticulocytes | 0.09 (−0.22 to 0.39); n=42 | 0.548 | 0.28 (−0.03 to 0.54); n=44 | 0.069 |
| Age | −0.09 (−0.37 to 0.21); n=46 | 0.556 | −0.17 (−0.44 to 0.13); n=47 | 0.251 |
Bold type reflects statistically significant results.
DRS, dose–response slope; SCD,sickle cell disease.